Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease

Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease Treated by Biological Therapy

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to assess the prevalence of exocrine pancreatic insufficiency (EPI) in a population of patients with active Crohn's disease. Studies already describe a prevalence rate around 18-66%. In this multicentric prospective study, we plan to compare EPI's prevalence at week 0 and week 14 of an induction phase of a biological therapy. The biological therapy will be initiate for an active Crohn's disease. Secondary outcomes will be: malnutrition's prevalence, and Crohn's disease activity level.

Who May Be Eligible (Plain English)

Who May Qualify: - Age of 18 years or more - Crohn's disease diagnosed for more than 3 months. - Active Crohn's disease : CDAI score \> 150 + \[CRP \> 5 mg/L or faecal calprotectin \> 250mcg/g or endoscopic lesion or MRI lesion\] - Indication of a biological therapy (anti-TNFα, vedolizumab ou ustekinumab). Who Should NOT Join This Trial: - Crohn's disease that doesn't fit the previous criteria - Extended resection of small intestine (\>40cm) - Chronic pancreatitis diagnosed before inclusion - Contraindication to biological therapy (anti-TNFα, vedolizumab ou ustekinumab) - Pancreatic enzyme replacement therapy - Pregnant or breastfeeding woman - Patient under the protection of a conservator Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age of 18 years or more * Crohn's disease diagnosed for more than 3 months. * Active Crohn's disease : CDAI score \> 150 + \[CRP \> 5 mg/L or faecal calprotectin \> 250mcg/g or endoscopic lesion or MRI lesion\] * Indication of a biological therapy (anti-TNFα, vedolizumab ou ustekinumab). Exclusion Criteria: * Crohn's disease that doesn't fit the previous criteria * Extended resection of small intestine (\>40cm) * Chronic pancreatitis diagnosed before inclusion * Contraindication to biological therapy (anti-TNFα, vedolizumab ou ustekinumab) * Pancreatic enzyme replacement therapy * Pregnant or breastfeeding woman * Patient under the protection of a conservator

Treatments Being Tested

BIOLOGICAL

Search for exocrine pancreatic insufficiency at week 0 and 12

We will collect 24 hours stool to search for steatorrhea, and to measure elastase and calprotectin. We will collect a total of 8 additional blood tubes (25mL), during regular blood sampling for a patient under biological therapy for a Crohn's disease. We will gather the total caloric and fat intake with a diet record.

Locations (1)

Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL
Pierre-Bénite, France